← Issue №18/ week of Nov 1, 2026/Hepatology

AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology guideline · Nov 1, 2026 · Gastroenterology · IF 25.1

AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis.

Guideline / reviewPBCguideline
Clinical takeawaySix recommendations: PBC-specific antinuclear antibodies in AMA-negative suspected PBC, UDCA first line, liver stiffness for prognosis, PPAR agonists for inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA after transplant to reduce recurrence. Certainty of evidence was moderate to very low.
What it foundThe guideline provides 6 recommendations, including UDCA as first-line therapy, liver stiffness measurement for prognostication, and linerixibat for moderate to severe pruritus, compared to older therapies like rifampin and naltrexone.
ContextThis guideline refines current practice by providing evidence-based recommendations for diagnosis, treatment escalation, symptom management, and post-transplantation care in adults with PBC.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance

Decision at stakethe use of UDCA as first-line therapy for PBC

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. … If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. … After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.

AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance · reviewed 2026-10-25 ↗
Levy C … Davitkov P · Gastroenterology · IF 25.1 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues